# Infectious Disease Sector Canonical URL: https://biopharmsignal.com/sector/infectious-disease Infectious Disease includes companies developing antivirals, antibiotics, vaccines, and other programs aimed at preventing or treating viral, bacterial, or fungal infections. It is a broad category that can span both commercial public health products and early-stage pipeline assets. Companies currently grouped under Infectious Disease: 31 ## Recent Sector News - 2026-10-07 12:45 EST — MBRX — [Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit](https://biopharmsignal.com/news/MBRX/moleculin-biotech-to-participate-in-advances-in-oncology-panel-at-the-2026-maxim-a29cb8b8) — Source: Moleculin Biotech, Inc. - 2026-10-06 12:45 EST — VIRI — [Dogwood to Participate in the 2026 Maxim Growth Summit](https://biopharmsignal.com/news/VIRI/dogwood-to-participate-in-the-2026-maxim-growth-summit-4369a08d) — Source: Virios Therapeutics - 2026-10-06 11:30 EST — SCYX — [SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)](https://biopharmsignal.com/news/SCYX/scynexis-announces-phase-1-study-results-for-scy-770-a-novel-highly-selective-or-452481ef) — Source: SCYNEXIS - 2026-10-05 14:00 EST — ASMB — [Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026](https://biopharmsignal.com/news/ASMB/assembly-biosciences-to-present-positive-phase-1a-safety-tolerability-and-target-4deba74a) — Source: Assembly Biosciences - 2026-10-02 21:05 EST — SPRO — [Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--f9d349b1) — Source: Spero Therapeutics - 2026-10-01 11:30 EST — ABUS — [Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer](https://biopharmsignal.com/news/ABUS/arbutus-announces-final-results-of-its-us-230-million-modified-dutch-auction-ten-98bcd9d8) — Source: Arbutus - 2026-09-30 11:30 EST — ABUS — [Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer](https://biopharmsignal.com/news/ABUS/arbutus-announces-preliminary-results-of-its-us-230-million-modified-dutch-aucti-b94b447f) — Source: Arbutus - 2026-09-29 12:45 EST — MBRX — [Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout](https://biopharmsignal.com/news/MBRX/moleculin-biotech-completes-enrollment-in-part-a-of-phase-2-3-r-r-aml-miracle-tr-779d914e) — Source: Moleculin Biotech, Inc. - 2026-09-29 12:00 EST — IMNN — [IMUNON Converts $1.2 Million of Debt-to-Equity](https://biopharmsignal.com/news/IMNN/imunon-converts-1-2-million-of-debt-to-equity-687dc896) — Source: Imunon - 2026-09-28 11:30 EST — SCYX — [SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247](https://biopharmsignal.com/news/SCYX/scynexis-awarded-barda-contract-providing-up-to-214-million-in-non-dilutive-fund-64556ba3) — Source: SCYNEXIS - 2026-09-28 11:00 EST — ANTX — [AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK](https://biopharmsignal.com/news/ANTX/an2-therapeutics-announces-extension-of-funding-for-tuberculosis-research-collab-554fb753) — Source: AN2 Therapeutics - 2026-09-28 11:00 EST — MBRX — [Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine](https://biopharmsignal.com/news/MBRX/moleculin-announces-publication-of-peer-reviewed-cardiac-safety-analysis-of-anna-4a0ddbf2) — Source: Moleculin Biotech, Inc. - 2026-09-25 17:05 EST — MBRX — [Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR](https://biopharmsignal.com/news/MBRX/annamycin-turns-cold-pancreatic-tumors-hot-in-new-preclinical-data-presented-at--ae640ee8) — Source: Moleculin Biotech, Inc. - 2026-09-24 12:05 EST — IMNN — [IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan](https://biopharmsignal.com/news/IMNN/imunon-makes-the-frontline-case-for-phase-3-imnn-001-study-14-7-month-os-signal--e9961969) — Source: Imunon - 2026-09-23 12:25 EST — MBRX — [Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040](https://biopharmsignal.com/news/MBRX/moleculin-biotech-secures-mexican-patent-protecting-lung-targeted-liposomal-anna-4a6ad586) — Source: Moleculin Biotech, Inc. - 2026-09-22 12:05 EST — IMNN — [IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review](https://biopharmsignal.com/news/IMNN/imunon-reports-independent-data-monitoring-committee-recommends-continued-phase--2a92e111) — Source: Imunon - 2026-09-22 12:00 EST — SCYX — [SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors](https://biopharmsignal.com/news/SCYX/scynexis-appoints-seasoned-industry-veteran-steven-k-burke-m-d-to-its-board-of-d-8bbc4089) — Source: SCYNEXIS - 2026-09-16 21:33 EST — ANTX — [AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ANTX/an2-therapeutics-inc-reports-inducement-grants-under-listing-rule-5635-c-4-1a06fe67) — Source: AN2 Therapeutics - 2026-09-15 12:00 EST — SCYX — [SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development](https://biopharmsignal.com/news/SCYX/scynexis-appoints-todd-minga-m-d-as-senior-vice-president-research-development-64a069a6) — Source: SCYNEXIS - 2026-09-14 12:45 EST — VIRI — [Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial](https://biopharmsignal.com/news/VIRI/dogwood-announces-completion-of-enrollment-in-ongoing-halneuron-phase-2b-trial-acb8f488) — Source: Virios Therapeutics ## Companies - [ACXP](https://biopharmsignal.com/company/ACXP) — Acurx Pharmaceuticals - [ANTX](https://biopharmsignal.com/company/ANTX) — AN2 Therapeutics - [ABUS](https://biopharmsignal.com/company/ABUS) — Arbutus - [ARDS](https://biopharmsignal.com/company/ARDS) — Aridis Pharmaceuticals - [ASMB](https://biopharmsignal.com/company/ASMB) — Assembly Biosciences - [AVIR](https://biopharmsignal.com/company/AVIR) — Atea - [BRNS](https://biopharmsignal.com/company/BRNS) — Barinthus Biotherapeutics - [BSLN](https://biopharmsignal.com/company/BSLN) — Basilea Pharmaceutica - [CDTX](https://biopharmsignal.com/company/CDTX) — Cidara Therapeutics - [CTXR](https://biopharmsignal.com/company/CTXR) — Citius Pharma - [COCP](https://biopharmsignal.com/company/COCP) — Cocrystal Pharma - [CFRX](https://biopharmsignal.com/company/CFRX) — ContraFect Corporation - [ENTA](https://biopharmsignal.com/company/ENTA) — Enanta Pharmaceuticals - [GOVX](https://biopharmsignal.com/company/GOVX) — GeoVax Labs - [GILD](https://biopharmsignal.com/company/GILD) — Gilead Sciences - [IMNN](https://biopharmsignal.com/company/IMNN) — Imunon - [INO](https://biopharmsignal.com/company/INO) — Inovio Pharmaceuticals - [ITRM](https://biopharmsignal.com/company/ITRM) — Iterum Therapeutics - [MLNTQ](https://biopharmsignal.com/company/MLNTQ) — Melinta Therapeutics - [MBRX](https://biopharmsignal.com/company/MBRX) — Moleculin Biotech, Inc. - [OPGN](https://biopharmsignal.com/company/OPGN) — OpGen - [OGEN](https://biopharmsignal.com/company/OGEN) — Oragenics - [SCYX](https://biopharmsignal.com/company/SCYX) — SCYNEXIS - [SIGA](https://biopharmsignal.com/company/SIGA) — SIGA Technologies Inc - [SPRO](https://biopharmsignal.com/company/SPRO) — Spero Therapeutics - [TLIS](https://biopharmsignal.com/company/TLIS) — Talis Biomedical Corp - [THTX](https://biopharmsignal.com/company/THTX) — Theratechnologies Inc. - [VLA](https://biopharmsignal.com/company/VLA) — Valneva - [VIR](https://biopharmsignal.com/company/VIR) — Vir Biotechnology - [VIRI](https://biopharmsignal.com/company/VIRI) — Virios Therapeutics - [YS](https://biopharmsignal.com/company/YS) — YS Biopharma